Glaxo to share malaria drug data

Pharmaceutical giant GlaxoSmithKline (GSK) will release 13,500 malaria drug candidates into the public domain as part of its ‘open innovation’ agenda, it announced on 20 January 2010. Chief executive Andrew Witty outlined the company’s strategy for increasing its intellectual property flexibility and altering its business model to tackle neglected tropical diseases. “We’re trying to identify […]

Read More Glaxo to share malaria drug data

The danger of drugs … and data

A fascinating court case in Australia has been playing out around some people who had heart attacks after taking the Merck drug ­Vioxx. This medication turned out to increase the risk of heart attacks in people taking it, although that finding was arguably buried in their research, and Merck has paid out more than £2bn […]

Read More The danger of drugs … and data